...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Role of extracellular Ca++ influx via L-type and non-L-type Ca++ channels in thromboxane A2 receptor-mediated contraction in rat aorta.
【24h】

Role of extracellular Ca++ influx via L-type and non-L-type Ca++ channels in thromboxane A2 receptor-mediated contraction in rat aorta.

机译:经由L型和非L型Ca ++通道的细胞外Ca ++流入在血栓烷A2受体介导的大鼠主动脉收缩中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of this study was to investigate the role of extracellular Ca++ influx via L-type and non-L-type Ca++ channels in thromboxane A2 receptor-mediated contraction. In intact rat aorta, U46619, a selective thromboxane A2 receptor agonist, induced concentration-dependent increases in intracellular Ca++ ([Ca++]i) and contraction (EC50 values of 5.5 and 6.1 nM, respectively). U46619 (10 nM) induced approximately 60 to 70% of maximal [Ca++]i elevation and contraction. Treatment with verapamil, an L-type Ca++ channel blocker, before 10 nM U46619 challenge, or during the plateau [Ca++]i elevation and contraction, decreased these parameters by approximately 50%. Ni++, a nonselective blocker of cation channels, or SKF96365, a purported blocker of receptor-operated Ca++ channels, further decreased the contraction and abolished the [Ca++]i elevation that remained after verapamil treatment of 10 nM U46619-challenged vessels. Pretreatment with verapamil and Ni++ to prevent Ca++ influx and with cyclopiazonic acid to deplete [Ca++]i stores also partially prevented U46619-induced contraction, whereas [Ca++]i elevation was abolished. These results suggest that thromboxane A2 receptor-mediated contraction of vascular smooth muscle partly depends on the influx of extracellular Ca++ via both L-type and non-L-type Ca++ channels, as well as a mechanism independent of [Ca++]i elevation.
机译:这项研究的目的是调查通过L型和非L型Ca ++通道的细胞外Ca ++流入在血栓烷A2受体介导的收缩中的作用。在完整的大鼠主动脉U46619(一种选择性的血栓烷A2受体激动剂)中,诱导浓度依赖性的细胞内Ca ++([Ca ++] i)增加和收缩(EC50值分别为5.5和6.1 nM)。 U46619(10 nM)诱导最大[Ca ++] i升高和收缩约60%至70%。在10 nM U46619攻击之前或在平台期[Ca ++] i升高和收缩期间,使用维拉帕米(一种L型Ca ++通道阻滞剂)治疗,可使这些参数降低约50%。 Ni ++是阳离子通道的非选择性阻滞剂,或据称是受体操纵的Ca ++通道的阻滞剂SKF96365,进一步降低了收缩并消除了维拉帕米处理10 nM U46619挑战性血管后残留的[Ca ++] i升高。用维拉帕米和Ni ++预处理以防止Ca ++大量涌入,以及用环吡唑酸消耗[Ca ++] i库,也可以部分阻止U46619诱导的收缩,而[Ca ++] i升高则被取消。这些结果表明,血栓烷A2受体介导的血管平滑肌收缩部分取决于通过L型和非L型Ca ++通道的细胞外Ca ++的流入,以及一种独立于[Ca ++] i升高的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号